G1 Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John E. Bailey Jr.
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 700 Park Offices Drive Research Triangle Park NC United States of America 27709
- IPO Date
- May 17, 2017
- CIK
- 0001560241
- Website
- g1therapeutics.com
- Similar Companies
- Business
- G1 Therapeutics, Inc. develops and commercializes small molecule therapeutics that protect bone marrow from chemotherapy-induced myelosuppression for patients with cancer; its lead product, COSELA (trilaciclib), is the first FDA-approved kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer (ES-SCLC) when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen. The company, founded in 2008 and headquartered in Research Triangle Park, North Carolina, focuses on oncology supportive care therapies targeting CDK4/6 pathways to transiently arrest hematopoietic stem and progenitor cells in the G1 phase of the cell cycle. It operates primarily in the United States with licensing agreements for trilaciclib in China and other regions through partners including Genor Biopharma and Simcere Pharmaceutical. COSELA, available as a 300 mg lyophilized powder for intravenous infusion, is administered at 240 mg/m2 over 30 minutes prior to chemotherapy on each treatment day; the company previously advanced trilaciclib in clinical trials for metastatic triple-negative breast cancer and bladder cancer, as well as lerociclib (CDK4/6 inhibitor) and Incyclix (CDK2 inhibitor) through partnerships. G1 Therapeutics serves oncologists and hospitals treating ES-SCLC patients, with efforts to expand COSELA's adoption amid chemotherapy shortages and supportive care needs in solid tumors. In September 2024, Pharmacosmos A/S completed its acquisition of G1 Therapeutics for $405 million in cash at $7.15 per share through a tender offer, making G1 a wholly owned subsidiary of Pharmacosmos Therapeutics Inc. and resulting in the delisting of G1's common stock from Nasdaq. The transaction, announced in August 2024, leverages Pharmacosmos' expertise in hematology supportive care products like Monoferric (ferric derisomaltose) to accelerate COSELA's commercialization in the US—where it launched in 2021—and pursue international regulatory approvals including in the UK and EU. This strategic combination enhances global access to multilineage myeloprotection for ES-SCLC patients while integrating G1's commercial infrastructure with Pharmacosmos' worldwide operations in over a dozen countries.
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
GTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
Pharmacosmos Group to Acquire G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
G1 Therapeutics' breast cancer drug fails in late-stage trial
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)